MCC-950, NLRP3 inflammasome inhibitor (TBI2990)

Description

Product Details

Formal Name: N-[[(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide sodium salt

Alternate Names: CRID3; CP-456773 sodium salt

Molecular Formula: C₂₀H₂₃N₂O₅S Na

Formula Weight: 426.46

CAS Number: 256373-96-3

Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to 40 mg/ml) or in Water (up to 30 mg/ml).

Storage: -20°C

Stability: ≥ 1 year.

 

Applications

NLRP3 inflammasome inhibitor

 

Functions

MCC-950 was originally found to act as a cytokine release inhibitory drug (CRID), arresting activated monocytes and preventing activation of caspase-1. Discovered to be a novel inhibitor of the NLRP3 and AIM2 inflammasomes. Blocks canonical and noncanonical NLRP3 activation at nanomolar concentrations. Inhibits interleukin 1β (IL-1β) secretion in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (an MS disease model). Disrupts the interaction between AIM2 and ASC in a reconstituted cell-free inflammasome. A valuable new tool for exploring the pathophysiology of NLRP.

 

Application Procedures

First dissolved in DMSO (up to 40 mg/ml) or in Water (up to 30 mg/ml), then diluted to aqueous buffer. Solutions in DMSO or distilled water may be stored at -20°C for up to 1 month.

Additional information

SIZE (mg)	25 MG, 5 MG

Datasheet:

TBI2990_MCC-950

MSDS:

TBI2990_MCC-950_MSDS_2024